NITROFURANTOIN Drug Patent Profile
✉ Email this page to a colleague
When do Nitrofurantoin patents expire, and what generic alternatives are available?
Nitrofurantoin is a drug marketed by Actavis Labs Fl Inc, Alembic, Athem, Aurobindo Pharma Usa, Impax Labs Inc, Mankind Pharma, Novel Labs Inc, Sun Pharm Industries, Watson Labs, Zydus Pharms, Actavis Mid Atlantic, Amneal Pharms, Aurobindo Pharma, Nostrum Labs Inc, Novitium Pharma, Elkins Sinn, Ivax Sub Teva Pharms, Sandoz, Whiteworth Town Plsn, Alvogen, Chartwell Rx, Inventia, Micro Labs, Ranbaxy Labs Ltd, Sunny, and Watson Labs Inc. and is included in thirty-nine NDAs.
The generic ingredient in NITROFURANTOIN is nitrofurantoin; nitrofurantoin, macrocrystalline. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the nitrofurantoin; nitrofurantoin, macrocrystalline profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NITROFURANTOIN?
- What are the global sales for NITROFURANTOIN?
- What is Average Wholesale Price for NITROFURANTOIN?
Summary for NITROFURANTOIN
US Patents: | 0 |
Applicants: | 26 |
NDAs: | 39 |
Finished Product Suppliers / Packagers: | 32 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 54 |
Patent Applications: | 6,113 |
Drug Prices: | Drug price information for NITROFURANTOIN |
What excipients (inactive ingredients) are in NITROFURANTOIN? | NITROFURANTOIN excipients list |
DailyMed Link: | NITROFURANTOIN at DailyMed |
Recent Clinical Trials for NITROFURANTOIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Early Phase 1 |
Walter Reed National Military Medical Center | Phase 2 |
Goodlife Pharma B.V. | Phase 4 |
Pharmacology for NITROFURANTOIN
Drug Class | Nitrofuran Antibacterial |
Medical Subject Heading (MeSH) Categories for NITROFURANTOIN
Anatomical Therapeutic Chemical (ATC) Classes for NITROFURANTOIN
US Patents and Regulatory Information for NITROFURANTOIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | NITROFURANTOIN | nitrofurantoin | TABLET;ORAL | 080043-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Amneal Pharms | NITROFURANTOIN | nitrofurantoin | SUSPENSION;ORAL | 201679-001 | May 11, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal Pharms | NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 207372-001 | May 15, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |